Tetra Discovery Partners Featured in Life Science Leader as a Company to Watch
Tetra Discovery Partners
A determined young company revisits a discarded mechanism and finds a new path to broad-based therapeutics for cognition-related diseases such as Alzheimer’s.
Tetra is developing a new class of phosphodiesterase 4 (PDE4)-inhibitor drugs to treat patients with a wide variety of “cognition-impairing” conditions. Its lead product, a PDE4D inhibitor (BPN14770), will enter Phase 1 human trials in Alzheimer’s disease this year, and two other pipeline candidates are PDE4B inhibitors in preclinical development for treating neuroinflammation and traumatic brain injury.